Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031949 | 0.81 | SLC6A2 (0.38) | CCR2KCNH2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5029381 | 0.80 | SLC6A4 (0.38) | CCR2KCNH2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5027120 | 0.75 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL5027117 | 0.75 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL5027115 | 0.75 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL17802168 | 0.67 | YTHDC1 (0.44) | SLC6A2SLC6A4MEN1KMT2AMAPK1 | |
| SCHEMBL17802169 | 0.67 | YTHDC1 (0.44) | SLC6A2SLC6A4MEN1KMT2AMAPK1 | |
| SCHEMBL21501961 | 0.66 | CYP3A4 (0.43) | CCR2KCNH2CYP2D6HPGD | |
| SCHEMBL28722408 | 0.64 | SLC6A2 (0.52) | SLC6A2SLC6A4MEN1KMT2ASLC18A3 | |
| SCHEMBL21227921 | 0.64 | SLC6A2 (0.52) | SLC6A2SLC6A4MEN1KMT2ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885KCNH2 1662/4885CYP2D6 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.